Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam S Cheifetz

Showing results (51-60 of 203) with videos related to

Pageof 21
Sort By:
Inflammatory Bowel Diseases|January 13, 2015
Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel diseaseJoseph D Feuerstein, Garret Cullen, Adam S Cheifetz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 21, 2018
ReplyKonstantinos Papamichael, Adam S Cheifetz, Mark T Osterman
Alimentary Pharmacology & Therapeutics|February 15, 2022
Review article: emerging drug therapies in inflammatory bowel diseaseLaurie B Grossberg, Konstantinos Papamichael, Adam S Cheifetz
Scandinavian Journal of Gastroenterology|May 17, 2024
Preactive therapeutic drug monitoring (TDM): time to redefine TDMKonstantinos Papamichael, Nurulamin M Noor, Adam S Cheifetz
Nature Clinical Practice. Gastroenterology & Hepatology|May 5, 2006
Combined oral and topical mesalazine treatment for extensive ulcerative colitisAlan C Moss, Adam S Cheifetz, Mark A Peppercorn
Alimentary Pharmacology & Therapeutics|March 22, 2022
Letter: is blindly stopping thiopurines without confirming adequate anti-TNF concentrations shortsighted?Natália Sousa Freitas Queiroz, Konstantinos Papamichael, Adam S Cheifetz
The American Journal of Gastroenterology|September 7, 2010
Capsule endoscopy in suspected Crohn's disease: "yield" does not equal "diagnosis"Glen A Doherty, Alan C Moss, Adam S Cheifetz
Journal of Crohn'S & Colitis|February 24, 2023
Going Beyond a Treat-To-Target to a Treat-To-Clear and a Treat-To-Trough Therapeutic Strategy in Patients with Inflammatory Bowel Disease?Natália Sousa Freitas Queiroz, Adam S Cheifetz, Konstantinos Papamichael
Expert Review of Gastroenterology & Hepatology|August 30, 2012
Comparative effectiveness research in inflammatory bowel disease: prospects and challengesJoseph D Feuerstein, Adam S Cheifetz, Corey A Siegel, et al.
Mayo Clinic Proceedings|June 20, 2014
In reply--Clinical practice guidelines: still miles to goJoseph D Feuerstein, Daniel A Leffler, Adam S Cheifetz
Pageof 21

Showing results (51-60 of 203) with videos related to

Sort By:
Pageof 21
Inflammatory Bowel Diseases|January 13, 2015
Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel diseaseJoseph D Feuerstein, Garret Cullen, Adam S Cheifetz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 21, 2018
ReplyKonstantinos Papamichael, Adam S Cheifetz, Mark T Osterman
Alimentary Pharmacology & Therapeutics|February 15, 2022
Review article: emerging drug therapies in inflammatory bowel diseaseLaurie B Grossberg, Konstantinos Papamichael, Adam S Cheifetz
Scandinavian Journal of Gastroenterology|May 17, 2024
Preactive therapeutic drug monitoring (TDM): time to redefine TDMKonstantinos Papamichael, Nurulamin M Noor, Adam S Cheifetz
Nature Clinical Practice. Gastroenterology & Hepatology|May 5, 2006
Combined oral and topical mesalazine treatment for extensive ulcerative colitisAlan C Moss, Adam S Cheifetz, Mark A Peppercorn
Alimentary Pharmacology & Therapeutics|March 22, 2022
Letter: is blindly stopping thiopurines without confirming adequate anti-TNF concentrations shortsighted?Natália Sousa Freitas Queiroz, Konstantinos Papamichael, Adam S Cheifetz
The American Journal of Gastroenterology|September 7, 2010
Capsule endoscopy in suspected Crohn's disease: "yield" does not equal "diagnosis"Glen A Doherty, Alan C Moss, Adam S Cheifetz
Journal of Crohn'S & Colitis|February 24, 2023
Going Beyond a Treat-To-Target to a Treat-To-Clear and a Treat-To-Trough Therapeutic Strategy in Patients with Inflammatory Bowel Disease?Natália Sousa Freitas Queiroz, Adam S Cheifetz, Konstantinos Papamichael
Expert Review of Gastroenterology & Hepatology|August 30, 2012
Comparative effectiveness research in inflammatory bowel disease: prospects and challengesJoseph D Feuerstein, Adam S Cheifetz, Corey A Siegel, et al.
Mayo Clinic Proceedings|June 20, 2014
In reply--Clinical practice guidelines: still miles to goJoseph D Feuerstein, Daniel A Leffler, Adam S Cheifetz
Pageof 21